Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iSCLife X-Unique is an umbilical cord-derived pluripotent stem cell therapy developed by Sclnow Biotechnology for endocrine repair, immune micro-lesion repair, and anti-aging applications. The therapy utilizes umbilical cord mesenchymal stem cells (UC-MSCs) that are cultured in vitro using a proprietary process to simulate the in-vivo microenvironment, which enhances stem cell characteristics such as repair-demand-induced migration and immune exemption. By strengthening the migration tropism of the stem cells, the therapy enables them to directly locate micro-lesions and damaged sites without immune rejection. The active cells work by activating dormant stem cell populations, replacing degenerating and aging tissue cells, restoring tissue and organ function, and improving cellular communication that typically deteriorates with age. The product is formulated with SCLnow-proprietary umbilical cord mesenchymal stem cells and a specific cryoprotectant accessory.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iSCLife X-Unique.